{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:47:54Z","timestamp":1740178074857,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["17\/56\/12"],"award-info":[{"award-number":["17\/56\/12"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Takeda UK Ltd to submit clinical- and cost-effectiveness evidence for brentuximab vedotin (BV) for treating relapsed or refractory CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The Liverpool Reviews and Implementation Group at the University of Liverpool was commissioned to act as the evidence review group (ERG). This article summarises the ERG\u2019s review of the company\u2019s submission for BV and the appraisal committee (AC) decision. The principal clinical evidence was derived from a subgroup of patients with advanced-stage CD30+ mycosis fungoides (MF) or primary cutaneous anaplastic large-cell lymphoma (pcALCL) in the phase III ALCANZA randomised controlled trial (RCT). This trial compared BV versus physician\u2019s choice (PC) of methotrexate or bexarotene. Evidence from three observational studies was also presented, which included patients with other CTCL subtypes. The ERG\u2019s main concerns with the clinical evidence were the lack of RCT evidence for CTCL subtypes other than MF or pcALCL, lack of robust overall survival data (data were immature and confounded by subsequent treatment and treatment crossover on disease progression) and lack of conclusive results from analyses of health-related quality-of-life data. The ERG noted that many areas of uncertainty in the cost-effectiveness analysis were related to the clinical data, arising from the rarity of the condition and its subtypes and the complexity of the treatment pathway. The ERG highlighted that the inclusion of allogeneic stem-cell transplant (alloSCT) as an option in the treatment pathway was based on weak evidence and generated more uncertainty in a disease area that, because of its rarity and diversity, was already highly uncertain. The ERG also lacked confidence in the company\u2019s modelling of the post-progression pathway and was concerned that it may not produce reliable results. Results from the company\u2019s base-case comparison (including a simple discount patient access scheme [PAS] for BV) showed that treatment with BV dominated PC. The ERG\u2019s revisions and scenario analyses highlighted the high level of uncertainty around the company base-case cost-effectiveness results, ranging from BV dominating PC to an incremental cost-effectiveness ratio per quality-adjusted life-year gained of \u00a3494,981. The AC concluded that it was appropriate to include alloSCT in the treatment pathway even though data were limited. The AC recommended BV as an option for treating CD30+ CTCL after at least one systemic therapy in adults if they have MF, stage IIB or higher pcALCL or S\u00e9zary syndrome and if the company provides BV according to the commercial arrangement (i.e. simple discount PAS).<\/jats:p>","DOI":"10.1007\/s41669-020-00203-0","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T14:02:58Z","timestamp":1584972178000},"page":"563-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"4","author":[{"given":"Angela","family":"Stainthorpe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Fleeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Houten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marty","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Beale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yenal","family":"Dundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"McEntee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Syndikus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"203_CR1","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. https:\/\/www.nice.org.uk\/guidance\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 6 Dec 2017."},{"key":"203_CR2","unstructured":"National Institute for Health and Care Excellence (NICE). Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma: technology appraisal guidance [TA577]. 2019. https:\/\/www.nice.org.uk\/guidance\/TA577. Accessed 7 Oct 2019."},{"issue":"16","key":"203_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703.","journal-title":"Blood"},{"issue":"3","key":"203_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjd.17240","volume":"180","author":"D Gilson","year":"2019","unstructured":"Gilson D, Whittaker S, Child F, Scarisbrick J, Illidge TM, Parry E, et al. British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180(3):496\u2013526.","journal-title":"Br J Dermatol"},{"issue":"11","key":"203_CR5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","volume":"149","author":"K Korgavkar","year":"2013","unstructured":"Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013;149(11):1295\u20139.","journal-title":"JAMA Dermatol"},{"key":"203_CR6","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation: Brentuximab vedotin for the treatment of cutaneous T-cell lymphoma (EMA\/COMP\/923105\/2011 Rev.2). https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Orphan_designation\/2012\/02\/WC500121705.pdf. Accessed 17 Aug 2018."},{"issue":"21","key":"203_CR7","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","volume":"113","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064\u201373.","journal-title":"Blood"},{"key":"203_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3389\/fonc.2019.00300","volume":"9","author":"FM Ghazawi","year":"2019","unstructured":"Ghazawi FM, Alghazawi N, Le M, Netchiporouk E, Glassman SJ, Sasseville D, et al. Environmental and other extrinsic risk factors contributing to the pathogenesis of cutaneous T cell lymphoma (CTCL). Front Oncol. 2019;9:300.","journal-title":"Front Oncol"},{"issue":"6","key":"203_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713\u201322.","journal-title":"Blood"},{"key":"203_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome\u2014update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer"},{"issue":"31","key":"203_CR11","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","volume":"28","author":"NS Agar","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730\u20139.","journal-title":"J Clin Oncol"},{"issue":"18","key":"203_CR12","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","volume":"18","author":"R Talpur","year":"2012","unstructured":"Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051\u201360.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"203_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/CCO.0000000000000311","volume":"28","author":"JJ Scarisbrick","year":"2016","unstructured":"Scarisbrick JJ. New drugs in cutaneous T-cell lymphomas. Curr Opin Oncol. 2016;28(5):384\u20139.","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"203_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0190-9622(03)02484-8","volume":"49","author":"HL Liu","year":"2003","unstructured":"Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49(6):1049\u201358.","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"203_CR15","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","volume":"118","author":"W Kempf","year":"2011","unstructured":"Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024\u201335.","journal-title":"Blood"},{"issue":"10","key":"203_CR16","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768\u201385.","journal-title":"Blood"},{"issue":"6","key":"203_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1001\/archdermatol.2009.74","volume":"145","author":"DK Woo","year":"2009","unstructured":"Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, Advani R, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145(6):667\u201374.","journal-title":"Arch Dermatol"},{"issue":"12","key":"203_CR18","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","volume":"95","author":"MW Bekkenk","year":"2000","unstructured":"Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653\u201361.","journal-title":"Blood"},{"issue":"6","key":"203_CR19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","volume":"149","author":"SJ Whittaker","year":"2003","unstructured":"Whittaker SJ, Marsden JR, Spittle M, Russell JR, British Association of D, Group UKCL. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol. 2003;149(6):1095\u2013107.","journal-title":"Br J Dermatol."},{"issue":"Suppl 6","key":"203_CR20","doi-asserted-by":"publisher","first-page":"vi149","DOI":"10.1093\/annonc\/mdt242","volume":"24","author":"R Willemze","year":"2013","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Group EGW. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi149\u2013vi154.","journal-title":"Ann Oncol."},{"issue":"8","key":"203_CR21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","volume":"42","author":"F Trautinger","year":"2006","unstructured":"Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome. Eur J Cancer. 2006;42(8):1014\u201330.","journal-title":"Eur J Cancer"},{"key":"203_CR22","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 2.2019 primary cutaneous lymphomas. 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf. Accessed 17 Oct 2018."},{"issue":"1","key":"203_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CF Hughes","year":"2015","unstructured":"Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71\u201381.","journal-title":"Blood"},{"key":"203_CR24","unstructured":"European Medicines Agency. Adcetris: brentuximab vedotin (EMEA\/H\/C\/002455). https:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002455\/human_med_001588.jsp&mid=WC0b01ac058001d124. Accessed 17 Aug 2018."},{"issue":"10094","key":"203_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, Drummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555\u201366.","journal-title":"Lancet"},{"issue":"32","key":"203_CR26","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","volume":"33","author":"M Duvic","year":"2015","unstructured":"Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759\u201365.","journal-title":"J Clin Oncol"},{"key":"203_CR27","unstructured":"Mathieu S, Ram-Wolff C, Quereux G, Oro S, Beylot-Barry M, Augbin F, et al. The French experience of treatment of cutaneous T cell lymphoma with brentuximab vedotin: a series of 32 cases. In: 3rd World congress of cutaneous lymphomas 2016. https:\/\/www.cutaneouslymphoma.org\/Portals\/0\/meeting_support\/3WCCL_Final_Program.pdf. Accessed 18 Oct 2019."},{"issue":"32","key":"203_CR28","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","volume":"33","author":"YH Kim","year":"2015","unstructured":"Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"203_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","volume":"30","author":"MM Chren","year":"2012","unstructured":"Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231\u20136 (xiii).","journal-title":"Dermatol Clin."},{"key":"203_CR30","unstructured":"EuroQoL Research Foundation. EQ-5D-3L. 2017. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-3l-about\/. Accessed 23 Aug 2018."},{"key":"203_CR31","unstructured":"European Medicines Agency. Assessment report: Adcetris. International non-proprietary name: brentuximab vedotin. Procedure No. EMEA\/H\/C\/002455\/II\/0048. 9 November 2017. EMA\/753623\/2017. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/002455\/WC500242962.pdf. Accessed 17 Aug 2018."},{"key":"203_CR32","unstructured":"NHS Improvement. Reference costs 2016\/17. 2017. https:\/\/improvement.nhs.uk\/resources\/reference-costs\/. Accessed 18 June 2018."},{"key":"203_CR33","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2018","unstructured":"Joint Formulary Committee. British National Formulary. London: BMJ Group and Pharmaceutical Press; 2018. http:\/\/www.medicinescomplete.com. Accessed 17 Aug 2018."},{"issue":"9","key":"203_CR34","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41409-018-0133-5","volume":"53","author":"M Debals-Gonthier","year":"2018","unstructured":"Debals-Gonthier M, Siani C, Faucher C, Touzani R, Lemarie-Basset C, Chabannon C, et al. Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone Marrow Transplant. 2018;53(9):1096\u2013104.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"203_CR35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0269216315595203","volume":"29","author":"J Round","year":"2015","unstructured":"Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat Med. 2015;29(10):899\u2013907.","journal-title":"Palliat Med"},{"key":"203_CR36","unstructured":"Monthly Index of Medical Specialities (MIMS). Bexarotene\u2014Targretin. 2018. https:\/\/www.mims.co.uk\/drugs\/cancer\/antineoplastics\/targretin. Accessed 24 May 2018."},{"key":"203_CR37","unstructured":"Monthly Index of Medical Specialities (MIMS). Methotrexate. 2018. https:\/\/www.mims.co.uk\/drugs\/cancer\/antineoplastics\/methotrexate-oral-solution. Accessed 24 May 2018."},{"key":"203_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008908.pub3","author":"M Schlaak","year":"2013","unstructured":"Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev. 2013. https:\/\/doi.org\/10.1002\/14651858.CD008908.pub3.","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"203_CR39","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","volume":"6","author":"SM Horwitz","year":"2008","unstructured":"Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and sezary syndrome: a stage-based approach. J Natl Compr Cancer Netw. 2008;6(4):436\u201342.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"14","key":"203_CR40","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/S0959-8049(01)00198-8","volume":"37","author":"M van Agthoven","year":"2001","unstructured":"van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uylde Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. A prospective randomised trial. Eur J Cancer. 2001;37(14):1781\u20139.","journal-title":"Eur J Cancer."},{"issue":"6","key":"203_CR41","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3109\/10428194.2014.970542","volume":"56","author":"P Swinburn","year":"2015","unstructured":"Swinburn P, Shingler S, Acaster S, Lloyd A, Bonthapally V. Health utilities in relation to treatment response and adverse events in relapsed\/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56(6):1839\u201345.","journal-title":"Leuk Lymphoma"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-020-00203-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-020-00203-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-020-00203-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:07:12Z","timestamp":1616458032000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-020-00203-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1007\/s41669-020-00203-0","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"23 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This project was funded by the National Institute for Health Research Health Technology Programme (Project number 17\/56\/12). See the Health Technology Assessment programme website for further project information (). The views and opinions expressed are those of the authors and do not necessarily reflect those of NICE or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Angela Stainthorpe, Nigel Fleeman, Rachel Houten, Marty Chaplin, Angela Boland, Sophie Beale, Yenal Dundar, Joanne McEntee and Isabel Syndikus have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}